GLP-1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
== History == Hohhot Baita Airport was opened on 1 October 1958. When it first opened to air traffic, it had only one dirt runway, three single‑story buildings, and five tents. The taxiway and apron were simple, and the runway measured 1,500 meters in length and 100 meters in width. In the mid-1980s and 1990s, it underwent two expansions and in June 2007 a new terminal was constructed. The new terminal covers an area of 54,499 square metres (586,620 sq ft) with 11 parking jetways and is capable of handling three million passengers each year. Its runway was also lengthened and its widened to accommodate jumbo jets such as the Airbus A380. It served as one of the diversion airports for air traffic during the 2008 Summer Olympics. With the rapid expansion of the city, Baita Airport is now surrounded by urban area and has no more room to expand to accommodate growing traffic. The Hohhot Shengle International Airport is being constructed in Horinger County which will replace Baita Airport and Baita is set to be closed once the new airport opened.
== History == IDLO was founded in 2016 to create tasty, healthy, and convenient meals for mountain hiking and expeditions. IDLO was the first company in Ukraine to package freeze-dried meals in doypacks, allowing users to prepare and consume meals directly from the pouch without the need for dishes. Its range of main courses is produced using freeze-drying technology at its facility, in accordance with food safety management systems compliant with ISO 22000/HACCP standards. Since 2020, the company has been supplying freeze-dried meals to the Ukrainian Antarctic research station Academician Vernadsky. The company's product line includes over 40 items, such as breakfasts, lunches, dinners, snacks, and beverages. Products are available in retail chains including Gorgany, Decathlon, and Intersport/Epicentr.
=== 19th century to WWII === From the end of the 19th century, systematic scientific and technical studies began on the processes of slowing down aging and possible rejuvenation. The period of world history between the two world wars is a very complicated, difficult and ambiguous time of world history. In many spheres of life, there were ideas that were radical-bold, but not always intelligent, ethical and moral from the point of view of modern knowledge, foundations and norms. This also affected the aging research, the spirit of which corresponded to the spirit of that time: attempting bold experiments, often on people, intensively implementing in practice treatments that we may now consider ridiculous. Those attempts had both bad and good consequences. But those researches were already scientific. As it often happens in science, it is often difficult to establish priority considering, who was the first person beginning to use one or another approach. Usually the first experiments are done by enthusiasts and have doubtful positive effects. Some researchers work in parallel. Then at some moment the persons emerge who developed the approaches and made them public.
Positive psychology has been implemented in business management practice, but has faced challenges. Wong & Davey (2007) noted managers can introduce positive psychology to a workplace, but they might struggle with positive ways to apply it to employees. Furthermore, for employees to welcome and commit to positive psychology, its application within an organization must be transparent. Managers must also understand the implementation of positive psychology will not necessarily combat any commitment challenges that exist. However, with its implementation employees might become more optimistic and open to new concepts or management practices. In their article "The Benefits of Frequent Positive Affect: Does Happiness Lead to Success?", S. Lyubomirsky et al. report: "Study after study shows that happiness precedes important outcomes and indicators of thriving, including fulfilling and productive work". Positive psychology, when applied correctly, can provide employees with a greater opportunity to use skills and vary work duties. However, changing work conditions and roles can lead to stress among employees if they are improperly supported by management. This is particularly true for employees who must meet the expectations of organizations with unrealistic goals and targets. Thomas and Tasker (2010) showed less worker autonomy, fewer opportunities for development, less-enriched work roles, and lower levels of supervisor support reflected the effect of industry growth on job satisfaction. Can an organization implement positive change? Lewis et al.
== Career == Chen began her career at the Institute of Chemistry of Academia Sinica as assistant research fellow in 1999. She was the Director of the Institute of Chemistry from 2013 to 2019, and is currently a Distinguished Research Fellow. She is also an adjunct professor at National Taiwan University, National Chiayi University, National Taiwan Ocean University, and National Chung Hsing University. She conducts research in mass spectrometry-based bioinformatics, in relation to understanding diseases such as cancer. Since 2016, Chen has participated in the US Cancer Moonshot Initiative, providing proteogenomics expertise as representative of Academia Sinica. She is the project investigator for the Taiwan Cancer Moonshot Project, which analyzes multiomic data related to gastric cancer. She participates in the Chromosome-centric Human Proteome Project, and is the group lead of chromosome 4. Chen served as president for the Human Proteome Organization (2021-2022), the Taiwan Proteomics Society, and the Taiwan Society for Mass Spectrometry (2012-2015). She has been a council member of the Asia Oceania Human Proteome Organization since 2019. She current serves as executive director of the Taiwan Proteomics Society (2021-2023), and the Taiwan Society for Mass Spectrometry. She served on editorial boards of European Journal of Mass Spectrometry, Journal of Proteome Research, and Frontiers in Analytical Chemistry, and currently serves on the Executive Advisory Board of Proteomics.
Sources: en.wikipedia.org
In 1867 the Swiss botanist Simon Schwendener upended orthodox lichen theory with a daring new hypothesis. In a lecture in September he argued that a lichen is a duo—a fungus that houses an alga—rather than a lone organism. His "dual hypothesis" cast the thallus as fungal tissue farming algal cells for photosynthate. Microscopy revealed algal 'gonidia' embedded in the fungal matrix, but many colleagues dismissed his reading. William Nylander repudiated the "composite" idea, viewing it as an affront to his life's work. The British lichenologist James Crombie derided the notion as a "master-and-slave" model—an enslaving parasitic fungus and its algal captive—and rebutted it in Encyclopædia Britannica. The dispute turned bitter, exposing both paradigm shock and the insularity of 19th-century lichenology. Despite the early backlash, proof for the dual hypothesis piled up during the 1870s–1880s. In 1872 Heinrich Anton de Bary—later to codify "symbiosis"—published work backing the fungal–algal alliance. Albert Frank coined "symbiose" in 1877 (de Bary anglicised it to "symbiosis" in 1879), recasting the partnership as mutualistic, not parasitic. Significantly, botanists started lab resynthesis—laboratory recreation of lichens from separated components. In 1873 Édouard Bornet matched lichen gonidia to free-living algae from 60-plus genera, proving the algae could live alone. Soon after, Hermann Reess (1872) grew fresh Collema thalli from fungal spores and algal cells; by 1886 Jules Bonnier had done the same with Xanthoria and other genera.
Methanogens rely on such enzymes to catalyze the reduction of CO2 to methane. One step in methanogenesis entails conversion of a methenyl group (formic acid oxidation state) to a methylene group (formaldehyde oxidation state). Among the hydrogenase family of enzymes, Hmd is unique in that it does not directly reduce CO2 to CH4. The natural substrate of the enzyme is the organic compound methenyltetrahydromethanopterin. The organic compound includes a methenyl group bound to two tertiary amines. The methenyl group originated as CO2 before being incorporated into the substrate, which is catalytically reduced by H2 to methylenetetrahydromethanopterin as shown. Eventually the methylene group is further reduced and released as a molecule of methane. The hydride transfer has also been shown to be stereospecific. Given that the substrate is planar the hydride originating from H2 is always added to the pro-R face. In the reverse reaction stereospecificity is maintained and the highlighted hydride is removed.
In 2017, PTC acquired Emflaza (deflazacort) from Marathon Pharmaceuticals. PTC also owns Translarna, (Ataluren) marketed for nonsense mutation Duchenne muscular dystrophy. Together, the two products generated revenues of 174 million dollars and 260 million dollars in 2017 and 2018 respectively. PTC has the commercialization rights for WAYLIVRA (volanesorsen) in Latin America. In 2018, PTC acquired Agilis Biotherapeutics and a gene therapy candidate, GT-AADC, with its compelling clinical data in treating aromatic L-amino acid decarboxylase (AADC) deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase (DDC) gene. As of 2024, the AAV based treatment for AADC deficiency has been approved by the FDA and commercialized in the United States as Kebilidi. It is the first FDA-approved gene therapy treatment for AADC deficiency. This same product was granted EMA approval for use in the European Union under the name Upstaza.
=== 1989 Kramatorsk, Ukraine === The 1989 Kramatorsk incident happened in 1989 when a small capsule 8 by 4 millimetres (0.3 by 0.2 inches) in size of caesium-137 was found inside the concrete wall of an apartment building in Kramatorsk, Ukrainian SSR. It is believed that the capsule, originally a part of a measurement device, was lost in the late 1970s and ended up mixed with gravel used to construct the building in 1980. Over 9 years, two families had lived in the apartment. By the time the capsule was discovered, 6 residents of the building had died, 4 from leukemia and 17 more receiving varying doses of radiation.
{\displaystyle \int _{V}{\frac {\partial E}{\partial t}}\,dV=-\oint _{\partial V}E{\mathbf {v} }\cdot d{\mathbf {A} }+\oint _{\partial V}({\mathbf {\sigma } \cdot v})\cdot d{\mathbf {A} }-\oint _{\partial V}{\mathbf {q} }\cdot d{\mathbf {A} }}
Sources: en.wikipedia.org
Jimmy John's Franchise, LLC, commonly referred to as Jimmy John's, is an American multinational sandwich chain, headquartered in Champaign, Illinois. The business was founded by Jimmy John Liautaud in 1983. After Liautaud graduated from high school, his father gave him a choice to either join the military or start a business. Liautaud decided to start a hot dog business, which changed to sandwiches due to costs. The Jimmy John's chain has over 2,800 locations, with 98% of them being franchises. In 2016, Roark Capital Group purchased a majority stake in the company. Later, in 2019, Inspire Brands purchased the company from Roark Capital Group for an unspecified amount.
== Absorption, metabolism, and excretion == Tocotrienols and tocopherols, the latter including the stereoisomers of synthetic alpha-tocopherol, are absorbed from the intestinal lumen, incorporated into chylomicrons, and secreted into the portal vein, leading to the liver. Absorption efficiency is estimated at 51% to 86%, and that applies to all of the vitamin E family – there is no discrimination among the vitamin E vitamers during absorption. Bile is necessary for chylomicron formation, so disease conditions such as cystic fibrosis result in biliary insufficiency and vitamin E malabsorption. When consumed as an alpha-tocopheryl acetate dietary supplement, absorption is promoted when consumed with a fat-containing meal. Unabsorbed vitamin E is excreted via feces. Additionally, vitamin E is excreted by the liver via bile into the intestinal lumen, where it will either be reabsorbed or excreted via feces, and all of the vitamin E vitamers are metabolized and then excreted via urine. Upon reaching the liver, RRR-alpha-tocopherol is preferentially taken up by alpha-tocopherol transfer protein (α-TTP). All other forms are degraded to 2'-carboxethyl-6-hydroxychromane (CEHC), a process that involves truncating the phytic tail of the molecule, then either sulfated or glucuronidated. This renders the molecules water-soluble and leads to excretion via urine. Alpha-tocopherol is also degraded by the same process, to 2,5,7,8-tetramethyl-2-(2'-carboxyethyl)-6-hydroxychromane (α-CEHC), but more slowly because it is partially protected by α-TTP.
== Measuring and processing the interferogram == The interferogram has to be measured from zero path difference to a maximum length that depends on the resolution required. In practice the scan can be on either side of zero resulting in a double-sided interferogram. Mechanical design limitations may mean that for the highest resolution the scan runs to the maximum OPD on one side of zero only. The interferogram is converted to a spectrum by Fourier transformation. This requires it to be stored in digital form as a series of values at equal intervals of the path difference between the two beams. To measure the path difference a laser beam is sent through the interferometer, generating a sinusoidal signal where the separation between successive maxima is equal to the wavelength of the laser (typically a 633 nm HeNe laser is used). This can trigger an analog-to-digital converter to measure the IR signal each time the laser signal passes through zero. Alternatively, the laser and IR signals can be measured synchronously at smaller intervals with the IR signal at points corresponding to the laser signal zero crossing being determined by interpolation. This approach allows the use of analog-to-digital converters that are more accurate and precise than converters that can be triggered, resulting in lower noise.
Most RTGs use 238Pu, which decays with a half-life of 87.7 years. RTGs using this material therefore diminish in power output by a factor of 1 – (1/2)1/87.7, or 0.787%, per year. One example is the MHW-RTG used by the Voyager probes. In the year 2000, 23 years after production, the radioactive material inside the RTG had decreased in power by 16.6%, i.e. providing 83.4% of its initial output; starting with a capacity of 470 W, after this length of time it would have a capacity of only 392 W. A related loss of power in the Voyager RTGs is the degrading properties of the bi-metallic thermocouples used to convert thermal energy into electrical energy; the RTGs were working at about 67% of their total original capacity instead of the expected 83.4%. By the beginning of 2001, the power generated by the Voyager RTGs had dropped to 315 W for Voyager 1 and to 319 W for Voyager 2. By 2022, these numbers had dropped to around 220 W. NASA has developed a multi-mission radioisotope thermoelectric generator (MMRTG) in which the thermocouples would be made of skutterudite, a cobalt arsenide (CoAs3), which can function with a smaller temperature difference than the current tellurium-based designs. This would mean that an otherwise similar RTG would generate 25% more power at the beginning of a mission and at least 50% more after seventeen years. NASA hopes to use the design on the next New Frontiers mission.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.